Last reviewed · How we verify
Durvalumab plus Olaparib
PD-1 inhibitor
PD-1 inhibitor Used for Urothelial carcinoma, Breast cancer.
At a glance
| Generic name | Durvalumab plus Olaparib |
|---|---|
| Sponsor | QuantumLeap Healthcare Collaborative |
| Drug class | Immune checkpoint inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Durvalumab is a monoclonal antibody that targets PD-L1, while Olaparib is a PARP inhibitor that targets BRCA1 and BRCA2. The combination of these two drugs may enhance anti-tumor activity by inhibiting DNA repair and immune checkpoint pathways.
Approved indications
- Urothelial carcinoma
- Breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer (PHASE1)
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... (PHASE1, PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (PHASE2)
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (PHASE2)
- Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
- Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer (PHASE2)
- AMTEC IIT: Phase 2 Multiarm Study in TNBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Durvalumab plus Olaparib CI brief — competitive landscape report
- Durvalumab plus Olaparib updates RSS · CI watch RSS
- QuantumLeap Healthcare Collaborative portfolio CI